Biosight raised €16M in a Series C round in Nov 2020. The company is based in Karmiel, Israel. Investors in the round: Israel Biotech Fund. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
